Finnegan NAS
Assess neonatal abstinence syndrome severity with the validated Finnegan Neonatal Abstinence Scoring System. Score 21 signs across CNS, autonomic, and GI categories with clinical treatment recommendations based on total score thresholds.
CNS Disturbances
Autonomic / Metabolic / Respiratory
GI Disturbances
About This Calculator
About the Finnegan Neonatal Abstinence Scoring System
The Finnegan Neonatal Abstinence Scoring System (FNASS), developed by Dr. Loretta Finnegan in 1975, is the most widely used clinical tool for assessing the severity of neonatal abstinence syndrome (NAS) in newborns exposed to opioids and other substances during pregnancy. This standardized scoring system helps healthcare providers determine whether non-pharmacological supportive care is sufficient or if pharmacological treatment is needed to manage withdrawal symptoms.
The scoring system evaluates 21 signs of withdrawal organized into three categories: CNS disturbances (cry pattern, sleep duration, Moro reflex, tremors, muscle tone, excoriation, myoclonic jerks, convulsions, and fever), autonomic/metabolic/respiratory signs (sweating, yawning, sneezing, nasal stuffiness, nasal flaring, tachypnea, and mottling), and GI disturbances (excessive sucking, poor feeding, regurgitation, and stool consistency). Each sign is scored based on severity, with higher scores indicating more severe withdrawal.
The total Finnegan score determines the clinical pathway: scores under 8 indicate mild symptoms manageable with supportive care alone (swaddling, reduced stimulation, rooming-in); scores of 8-11 suggest initiating pharmacological treatment (typically oral morphine or methadone); and scores above 11 confirm severe NAS requiring prompt pharmacotherapy. The score is typically reassessed every 3-4 hours and more frequently during medication titration.
NAS occurs when a fetus is exposed to addictive substances (particularly opioids) during pregnancy and experiences withdrawal after birth. Common causative substances include heroin, methadone, buprenorphine, oxycodone, and other prescription opioids. The incidence of NAS has risen dramatically with the opioid epidemic, affecting approximately 7-8 per 1,000 hospital births in the United States as of recent estimates.
Global Guidelines for NAS Assessment
United States: The American Academy of Pediatrics (AAP) recommends using a standardized assessment tool like the Finnegan score for all opioid-exposed newborns. The 2020 AAP guidelines emphasize non-pharmacological care as first-line treatment and recommend monitoring for at least 72 hours after birth (4-7 days for buprenorphine-exposed infants).
United Kingdom: NICE guidelines recommend monitoring infants at risk of NAS using a validated scoring system. Midwives and neonatal nurses are trained in the Finnegan or modified Finnegan scoring. The UK also emphasizes family-centered care, breastfeeding support, and avoiding unnecessary NICU admissions.
India: With rising rates of prescription opioid use, Indian neonatology units increasingly adopt the Finnegan scoring system, particularly in tertiary care centers. The Indian Academy of Pediatrics recommends standardized assessment and treatment protocols similar to international guidelines, adapted for local resources and substance use patterns.
Frequently Asked Questions
What is the Finnegan Neonatal Abstinence Scoring System?
The Finnegan Neonatal Abstinence Scoring System (FNASS) is a validated clinical tool developed by Dr. Loretta Finnegan in 1975 to assess the severity of neonatal abstinence syndrome (NAS) in newborns exposed to opioids or other substances in utero. It scores 21 signs grouped into CNS disturbances, autonomic/metabolic/respiratory signs, and GI disturbances, with a total score range of 0 to approximately 46. Scores under 8 suggest mild symptoms manageable with supportive care, scores 8-11 indicate a need to consider pharmacotherapy, and scores above 11 require pharmacological intervention.
How is the Finnegan score calculated?
The Finnegan score is calculated by observing the infant and assigning numerical scores to 21 signs of withdrawal across three categories: CNS disturbances (cry pattern, sleep after feeding, Moro reflex, tremors, muscle tone, excoriation, myoclonic jerks, convulsions, fever), autonomic/metabolic/respiratory signs (sweating, yawning, sneezing, nasal stuffiness, nasal flaring, tachypnea, mottling), and GI disturbances (excessive sucking, poor feeding, regurgitation, stool consistency). Each sign is scored 0-5 based on severity, and the scores are summed to produce a total. Scores of 0-7 indicate mild NAS, 8-11 moderate NAS, and 12+ severe NAS.
What score indicates treatment for neonatal abstinence syndrome?
In the Finnegan scoring system, a total score of 8 or higher typically indicates the need to initiate pharmacological treatment for neonatal abstinence syndrome. Scores of 8-11 suggest starting opioid therapy (oral morphine or methadone) per institutional protocol. Scores above 11 indicate that pharmacotherapy is required, and the opioid dose may need to be increased. Some institutions have modified thresholds, but the traditional Finnegan protocol uses a cutoff of 8 for initiating treatment. Always follow your hospital's specific NAS management protocol.
What are the signs of neonatal abstinence syndrome?
Neonatal abstinence syndrome (NAS) signs include CNS disturbances such as high-pitched crying, tremors, hyperactive Moro reflex, increased muscle tone, myoclonic jerks, and seizures; autonomic signs such as sweating, fever, frequent yawning and sneezing, nasal stuffiness, tachypnea, and skin mottling; and GI disturbances such as excessive sucking, poor feeding, regurgitation, projectile vomiting, and loose or watery stools. Symptoms typically appear within 24-72 hours after birth for short-acting opioids and may be delayed 5-14 days for longer-acting substances like methadone.
How often should the Finnegan score be assessed?
The Finnegan score should be assessed every 3-4 hours in newborns at risk for neonatal abstinence syndrome. Scoring is typically performed before and after feedings to capture the full range of symptoms. During pharmacological treatment, scores are assessed every 2-4 hours after each medication dose to evaluate response and guide dose adjustments. Once the infant is stabilized and doses are being weaned, the assessment frequency may be reduced to every 4-6 hours. Consistent scoring by trained nursing staff is essential for reliable results.
Can non-pharmacological interventions help neonatal abstinence syndrome?
Yes, non-pharmacological interventions are the first-line treatment for NAS and can significantly reduce symptom severity. Key interventions include swaddling the infant, minimizing environmental stimuli (dim lights, reduce noise), rooming-in with the mother to promote bonding, breastfeeding (if mother is not using illicit drugs), on-demand feeding, gentle rocking, skin-to-skin contact, and clustering care to minimize disturbances. Studies show that these supportive measures alone can manage mild NAS (scores under 8) without medication, and they reduce the duration and dosage of pharmacotherapy in moderate to severe cases.
What is the prognosis for infants with neonatal abstinence syndrome?
With appropriate treatment, most infants with NAS recover fully from the acute withdrawal phase. Hospital stays typically range from 15-30 days for pharmacologically treated infants. Long-term outcomes vary; some studies show increased risk of developmental delays, behavioral problems, and cognitive difficulties in childhood. However, a nurturing home environment, early intervention services, and avoidance of future substance exposure significantly improve outcomes. Infants with NAS also have higher rates of low birth weight, prematurity, and sudden infant death syndrome (SIDS), so close follow-up is recommended.
What medications are used to treat neonatal abstinence syndrome?
First-line pharmacological treatment for NAS is oral opioid replacement therapy, typically morphine solution or methadone. These are started when Finnegan scores are consistently 8 or higher despite optimal non-pharmacological care. The medication is started at a calculated dose based on the infant's weight and Finnegan score, then gradually weaned over days to weeks as symptoms improve. Adjunct medications include phenobarbital (especially for seizures or polydrug exposure), clonidine (as a second-line agent to reduce autonomic symptoms), and buprenorphine (increasingly used as an alternative first-line agent with shorter treatment duration).